Safety and efficacy of pamrevlumab (FG-3019) in patients with COVID-19 pneumonia: an open-label, randomized, parallel-arm phase 2 study
G. Sgalla (Rome, Italy), J. Simonetti (Rome, Italy), G. Gualano (Rome, Italy), P. Maria Leone (Rome, Italy), A. Comes (Rome, Italy), D. Verdirosi (Rome, Italy), L. Poole (San Francisco, United States), E. Kouchakji (San Francisco, United States), F. Palmieri (Rome, Italy), L. Richeldi (Rome, Italy), J. Simonetti (Rome, Italy)
Source: International Congress 2022 – COVID treatments
Session: COVID treatments
Session type: Thematic Poster
Number: 2609
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Sgalla (Rome, Italy), J. Simonetti (Rome, Italy), G. Gualano (Rome, Italy), P. Maria Leone (Rome, Italy), A. Comes (Rome, Italy), D. Verdirosi (Rome, Italy), L. Poole (San Francisco, United States), E. Kouchakji (San Francisco, United States), F. Palmieri (Rome, Italy), L. Richeldi (Rome, Italy), J. Simonetti (Rome, Italy). Safety and efficacy of pamrevlumab (FG-3019) in patients with COVID-19 pneumonia: an open-label, randomized, parallel-arm phase 2 study. 2609
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|